Brexpiprazole (Rexulti)

How Medicare covers it

Part D (forms used at home). Part A during a covered inpatient stay. No Part B clinician-administered form in the CMS Part B spending file.

What it treats

Brexpiprazole (Rexulti) is an atypical antipsychotic tablet with three labeled uses: as an add-on (adjunctive) treatment to antidepressants for major depressive disorder (MDD) in adults; treatment of schizophrenia in adults and in pediatric patients 13 years and older; and treatment of agitation associated with dementia due to Alzheimer's disease. It is not indicated as an as-needed ('prn') treatment for that agitation.

What it is for, in depth

From the label's Indications section, Rexulti's three roles are distinct. (1) Adjunctive treatment to antidepressants for MDD in adults — prescribed when an antidepressant alone has not done enough, at the lowest dose range (target 2 mg/day). (2) Treatment of schizophrenia in adults and adolescents 13+ (target 2–4 mg/day). (3) Treatment of agitation associated with dementia due to Alzheimer's disease (target 2 mg/day) — the use most specific to this site's readership, and the label fences it carefully: it is a scheduled daily treatment, not an as-needed sedative (explicitly not indicated as a 'prn' treatment), and the boxed warning states Rexulti is not approved for dementia-related psychosis without agitation associated with Alzheimer's dementia. Who it is prescribed for follows those fences: an adult with depression on an antidepressant that needs a boost, a person with schizophrenia, or an Alzheimer's patient with persistent agitation — in every case as daily maintenance, with the class warnings (metabolic monitoring, movement disorders, falls, fainting) actively managed. Forms in the formulary data behind this page: Rexulti tablets of 0.25, 0.5, 1, 2, 3, and 4 mg, brand only.

How it works

Brexpiprazole is an atypical antipsychotic. The label says its mechanism of action in these conditions is unknown, but its efficacy may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist (blocking) activity at serotonin 5-HT2A receptors — a partial-agonist profile intended to steady dopamine and serotonin signaling rather than simply block it.

How it is taken

Tablets of 0.25, 0.5, 1, 2, 3, and 4 mg, taken once daily with or without food. For adjunctive MDD: start 0.5 or 1 mg/day, target 2 mg/day, maximum 3 mg/day. For schizophrenia: start 1 mg/day, target 2–4 mg/day, maximum 4 mg/day. For agitation associated with Alzheimer's dementia: start 0.5 mg/day, target 2 mg/day, maximum 3 mg/day. Maximum doses are lower in moderate-to-severe liver impairment and when creatinine clearance is under 60 (2 mg/day for MDD and Alzheimer's agitation; 3 mg/day for schizophrenia), and the dose is halved or quartered with certain CYP inhibitors (see interactions).

Common side effects

The label extract's adverse-reactions section names the reaction classes detailed in its warnings (below) rather than a frequency table: cerebrovascular events in elderly dementia patients, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (high blood sugar/diabetes, cholesterol changes, weight gain), pathological gambling and other compulsive behaviors, low white blood cell counts, orthostatic hypotension and fainting, falls, seizures, body-temperature dysregulation, swallowing problems (dysphagia), and cognitive and motor impairment.

Serious warnings

The two boxed warnings are stated above; the same elderly dementia population also shows an increased incidence of cerebrovascular adverse reactions including stroke and transient ischemic attack. Other warnings: neuroleptic malignant syndrome (a rare, life-threatening reaction — stop immediately and monitor closely); tardive dyskinesia (involuntary movements that may not reverse — stop if clinically appropriate); metabolic changes — monitor for high blood sugar/diabetes, lipid changes, and weight gain; pathological gambling and other compulsive behaviors — consider dose reduction or stopping; leukopenia, neutropenia, and agranulocytosis (low white cells — blood counts in patients with low WBC history); orthostatic hypotension and syncope (fainting) — monitor heart rate and blood pressure in patients with cardiovascular or cerebrovascular disease or dehydration risk; falls; seizures (caution with seizure history); body temperature dysregulation; dysphagia (swallowing difficulty); and potential for cognitive and motor impairment (caution operating machinery). Third-trimester pregnancy exposure may cause extrapyramidal and/or withdrawal symptoms in newborns. It is contraindicated in hypersensitivity to brexpiprazole (reactions included rash, facial swelling, hives, and anaphylaxis).

Boxed warning

BOXED WARNING (stated plainly): (1) INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS — Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease. (2) SUICIDAL THOUGHTS AND BEHAVIORS — Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

Who should be careful

Elderly patients with dementia (both boxed warnings converge here — increased mortality with antipsychotics, and stroke risk); children and young adults on antidepressant therapy (suicidal thoughts monitoring); people with diabetes risk or weight concerns (metabolic monitoring); people with low white-cell counts; people with cardiovascular or cerebrovascular disease or dehydration (fainting risk); people with seizure history; patients who are CYP2D6 poor metabolizers or who take CYP inhibitors/inducers (dose adjustments); people with moderate-to-severe liver impairment or kidney clearance under 60 (lower maximums); and patients exposed in the third trimester of pregnancy (newborn withdrawal/movement symptoms).

Major interactions

The label's dose-adjustment table is built on CYP enzymes: strong CYP2D6 or CYP3A4 inhibitors — administer half the recommended dosage (with a stated exception for adjunctive MDD use with strong CYP2D6 inhibitors such as paroxetine or fluoxetine, where no adjustment is made because the antidepressant doses already account for it); combined strong/moderate CYP2D6 with strong/moderate CYP3A4 inhibitors — administer a quarter of the recommended dosage; known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors — a quarter of the dosage; strong CYP3A4 inducers — double the recommended dosage and adjust further by clinical response.

Cost and saving notes

Rexulti is a brand-only product, and in the CMS data behind this page it most often sits on the specialty tier — Tier 5 (see the tier section) — where patients pay a percentage of a high price rather than a flat copay. That is the most expensive placement in Part D. A tier exception, Extra Help for people with limited income, and confirming the plan's exact coinsurance before filling are the practical steps.

Why it is in its tier

Brexpiprazole (Rexulti) sits on Tier 5 in 78.2% of the plans that list it (4297 of 5495 listing plans). Tier 5 is the specialty tier — instead of a flat copay, patients usually pay a percentage of the drug's cost (coinsurance), which is why specialty drugs feel expensive even with coverage. The data-visible drivers: It is a brand-only product with no generic version in the formulary data, and the CMS dashboard puts its average Part D spending at about $9,096 per beneficiary for 2024 — a high-cost drug, which matches where plans place it. It is listed by 100.0% of Part D plans. The tier shown is the most common one; individual plans vary.

Sources

• REXULTI (BREXPIPRAZOLE) TABLET REXULTI (BREXPIPRAZOLE) KIT [OTSUKA AMERICA PHARMACEUTICAL, INC.] — DailyMed
• MedlinePlus — National Library of Medicine
• MedlinePlus — Brexpiprazole

What official patient guides say

Brexpiprazole comes as a tablet to take by mouth, once daily with or without food, at around the same time every day. Take it exactly as directed — do not take more, less, or take it more often than prescribed. Your doctor may start you on a low dose and gradually increase your dose depending on how well the medication works for you and the side effects you have. Brexpiprazole may control your symptoms but will not cure your condition. Continue to take it even if you feel well, and do not stop taking it without talking to your doctor. If you miss a dose, take it as soon as you remember it. If it is almost time for the next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose. Keep it in the container it came in, tightly closed and out of reach of children. Store it at room temperature, away from extra heat and moisture, and not in the bathroom.

Source: MedlinePlus — Brexpiprazole

Part D formulary coverage

Source: CMS Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files — Monthly file 2026-10-15 (plan year 2027), file 2027_20261008.zip (data.cms.gov dataset ed1496ea-23e7-41f1-9292-172fa842ccfb): basic drugs formulary file + plan information file, both dated 20261031 inside the zip; downloaded and aggregated 2026-10-30. Medication RxCUI sets resolved through the NLM RxNav (RxNorm) API.

What you pay

Without insurance, the cash benchmark is 49.49046 per unit (REXULTI 0.25 MG TABLET) — about nan for 30 units. NADAC benchmark — the average price pharmacies pay (CMS, as of 2026-11-04). Pharmacy shelf prices vary.

A tier is not a price; what you pay depends on your plan, pharmacy, and benefit stage; Extra Help or Medicaid can lower it further.

Sources: CMS Plan Benefit Package + formulary data; CMS NADAC · Checked 2026-11-07

Coverage by plan and tier

Of the 5,495 Medicare drug plans we track for 2027, 5,495 list Brexpiprazole (Rexulti) — 100% of plans. Most of those plans put it on Tier 5: 4,297 plans, 78.2% of the plans that list it. Other plans place it on Tier 4 (1,074 plans), Tier 1 (123 plans) or Tier 2 (1 plans). For example: Aetna Medicare Dual Extra (HMO D-SNP) puts it on Tier 5; Aetna Medicare Dual Extra Care (PPO D-SNP) puts it on Tier 5; Aetna Medicare Value Plus (PPO) puts it on Tier 5. You can compare these plans side by side on our Medicare Advantage hub. A tier is not a price. What you pay also depends on whether you have met your plan';s deductible, whether the drug costs a flat copay or a share of the price, and whether you get Extra Help or Medicaid.

Read next

• Part D in 2027: The $700 Deductible, the $2,400 Cap, and the $35 Insulin Rule
• Extra Help in 2027: Lower Drug Copays and Who Qualifies
• Checking Medicare Savings Programs and Extra Help

Part D spending averages (2024)

Source: CMS Medicare Part D Spending by Drug (Drug Spending Dashboard), release RY26 P04 V10, data through 2024 (DSD_PTD_RY26_P04_V10_DY24_BGM.csv), downloaded 2026-10-30

Companies covering this drug

Part D and Medicare Advantage plan sponsors that list this drug on a formulary, 50 at a time.